Sanofi hires Mike Quigley as next chief scientist, internal memo says

Andrew Dunn

Senior Biopharma Correspondent

Sanofi has appointed Mike Quigley, a former executive at Gilead and Bristol Myers Squibb, as the French pharma’s next chief scientific officer, Endpoints News …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi hires Mike Quigley as next chief scientist, internal memo says

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Updated: Gene therapy maker bluebird bio cuts costs again, lays off staff

Biogen, UCB declare Phase 3 lupus win and prep a second trial, but details are scant

Wave rides new Phase 2 DMD data as it sets sights on accelerated approval

Flagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first clinical readouts near

Clive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with an eye on Phase 3 next year

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Sanofi hires Mike Quigley as next chief sci­en­tist, in­ter­nal memo says

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Up­dat­ed: Gene ther­a­py mak­er blue­bird bio cuts costs again, lays off staff

Bio­gen, UCB de­clare Phase 3 lu­pus win and prep a sec­ond tri­al, but de­tails are scant

Wave rides new Phase 2 DMD da­ta as it sets sights on ac­cel­er­at­ed ap­proval

Flag­ship’s AI biotech Gen­er­ate lands $65M up­front in No­var­tis deal, as first clin­i­cal read­outs near

Clive Mean­well's new obe­si­ty biotech, Met­sera, un­veils ear­ly GLP-1 da­ta with an eye on Phase 3 next year

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

Sanofi hires Mike Quigley as next chief scientist, internal memo says

Updated: Gene therapy maker bluebird bio cuts costs again, lays off staff

Biogen, UCB declare Phase 3 lupus win and prep a second trial, but details are scant

Wave rides new Phase 2 DMD data as it sets sights on accelerated approval

Flagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first clinical readouts near

Clive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with an eye on Phase 3 next year

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships